Humana (NYSE:HUM) Announces Earnings Results, Beats Expectations By $1.25 EPS

Humana (NYSE:HUMGet Rating) posted its quarterly earnings data on Wednesday. The insurance provider reported $8.04 EPS for the quarter, beating analysts’ consensus estimates of $6.79 by $1.25, MarketWatch Earnings reports. The company had revenue of $23.97 billion during the quarter, compared to analysts’ expectations of $23.54 billion. Humana had a return on equity of 17.27% and a net margin of 3.51%. Humana’s revenue for the quarter was up 16.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $7.67 earnings per share.

Shares of Humana stock opened at $444.56 on Friday. The stock has a 50 day moving average of $440.69 and a 200 day moving average of $435.16. Humana has a 12 month low of $351.20 and a 12 month high of $475.44. The firm has a market cap of $56.34 billion, a PE ratio of 18.86, a PEG ratio of 1.35 and a beta of 0.94. The company has a current ratio of 1.53, a quick ratio of 1.62 and a debt-to-equity ratio of 0.74.

The company also recently declared a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Thursday, June 30th will be paid a dividend of $0.7875 per share. This represents a $3.15 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date of this dividend is Wednesday, June 29th. Humana’s payout ratio is presently 13.36%.

A number of analysts have commented on the company. UBS Group upgraded Humana from a “neutral” rating to a “buy” rating and upped their price target for the stock from $486.00 to $520.00 in a research report on Wednesday, April 13th. Barclays reduced their price target on Humana from $540.00 to $490.00 and set an “overweight” rating for the company in a research report on Friday, January 7th. Truist Financial upped their price target on Humana from $460.00 to $490.00 in a research report on Thursday, April 7th. SVB Leerink reduced their price target on Humana from $528.00 to $525.00 and set an “outperform” rating for the company in a research report on Thursday, February 3rd. Finally, StockNews.com upgraded Humana from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, April 20th. Seven analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $486.28.

Several large investors have recently bought and sold shares of the company. Visionary Wealth Advisors bought a new stake in shares of Humana in the 4th quarter valued at approximately $259,000. EP Wealth Advisors LLC lifted its stake in shares of Humana by 9.9% in the 4th quarter. EP Wealth Advisors LLC now owns 753 shares of the insurance provider’s stock valued at $349,000 after purchasing an additional 68 shares during the last quarter. NewEdge Advisors LLC lifted its stake in shares of Humana by 118.1% in the 4th quarter. NewEdge Advisors LLC now owns 2,445 shares of the insurance provider’s stock valued at $1,134,000 after purchasing an additional 1,324 shares during the last quarter. Zullo Investment Group Inc. bought a new stake in shares of Humana in the 4th quarter valued at approximately $110,000. Finally, Horizon Investments LLC lifted its stake in shares of Humana by 8.5% in the 4th quarter. Horizon Investments LLC now owns 921 shares of the insurance provider’s stock valued at $427,000 after purchasing an additional 72 shares during the last quarter. 92.96% of the stock is owned by institutional investors and hedge funds.

About Humana (Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also

Earnings History for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.